Physician profile
William E Cobb
NPI 1619927670
$6,785.80
in general payments reported to CMS, 2019-2025
34 companies · $20.60 in 2025
The $20.60 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,133 · 2020: $1,636 · 2021: $1,899 · 2022: $97.28 · 2025: $20.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,258.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $804.49 | 2019-2022 | |
| Amgen INC. | $660.45 | 2019-2021 | |
| Lilly USA, LLC | $458.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.82 | 2019-2022 | |
| Abbvie INC. | $420.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $343.15 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $336.55 | 2019-2021 | |
| Amarin Pharma, INC. | $256.24 | 2019-2020 | |
| Vifor Pharma, INC. | $239.72 | 2019-2021 | |
| Valeritas, INC. | $198.46 | 2019 | |
| Lifescan, INC. | $178.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $174.68 | 2019-2020 | |
| Corcept Therapeutics | $160.63 | 2019-2021 | |
| Esperion Therapeutics, INC. | $118.97 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $103.00 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $100.11 | 2019-2021 | |
| Pfizer INC. | $65.79 | 2019-2025 | |
| Medtronic Minimed, INC. | $50.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.27 | 2021 | |
| Xeris Pharmaceuticals, INC. | $47.43 | 2021 | |
| Radius Health, INC. | $39.43 | 2019 | |
| Medtronic, INC. | $34.11 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $34.01 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.68 | 2021 | |
| Mallinckrodt Enterprises LLC | $22.70 | 2019 | |
| Opko Pharmaceuticals, LLC | $22.67 | 2021 | |
| Ibsa Pharma INC. | $20.98 | 2019 | |
| Amryt Pharma Holdings Ltd | $20.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.46 | 2019 | |
| Ascensia Diabetes Care US INC. | $19.04 | 2021 | |
| Akebia Therapeutics INC | $18.15 | 2019 | |
| Alfasigma USA, INC. | $17.67 | 2021 | |
| Tandem Diabetes Care, INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.